v3.26.1
Segment Reporting (Tables)
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Operating Expenses of Our Clinical Stage Drug Development Segment

The following table provides the operating expenses of our clinical stage drug development segment (rounded to the nearest $00):

 

   March 31,   March 31, 
   2026   2025 
Clinical Study Expense  $1,471,100   $7,960,600 
Other Research Expense   1,118,400    1,831,000 
Manufacturing and Drug Storage Expense   2,784,200    155,600 
Compensation Expense   1,674,500    933,500 
Stock-based Compensation Expense   1,039,600    1,070,300 
Total Research and Development Expense  $8,087,800   $11,951,000